Antibody and Development - Clinical Research Informer

A startup raises $336M to make a better antibody drug for COVID-19

Bio Pharma Dive

APRIL 19, 2021

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.

Antibody

Antibody Drugs Development

Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback

Bio Pharma Dive

SEPTEMBER 14, 2020

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020.

Genetics

Genetics Antibody Drugs Development

Citryll gains Series B funds to develop NET-targeting antibody

Pharmaceutical Technology

DECEMBER 9, 2024

Citryll has secured an oversubscribed Series B funding round, raising 85m ($89.8m) to advance the clinical development of CIT-013.

Development

Development Antibody Clinical Development

Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

Bio Pharma Dive

JULY 28, 2021

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.

Antibody

Antibody Drugs Development

Twist Bioscience and Astellas team up for antibody discovery

Pharmaceutical Technology

APRIL 21, 2023

Twist Bioscience and Astellas Pharma have entered a collaboration to help the latter to discover antibodies for immunotherapies. In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression.

Antibody

Antibody Licensing Licensing Protein

Talem and Libera Bio partner for discovery of AI-driven antibodies

Pharmaceutical Technology

MARCH 16, 2023

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

Antibody

Antibody In-Vivo Pharma Companies Protein

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

OCTOBER 14, 2020

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19.

Antibody

Antibody FDA Approval Drugs Development

Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody

Antibody Immune Response Protein Development

Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody

Antibody Genotype Development Licensing

AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In May, the company supplied the first doses of the antibody therapy to Swiss hospitals for Covid-19 prevention.

Antibody

Antibody Compliance Clinical Trials Clinical Trials

Astellas and Sutro partner to develop immunostimulatory ADCs

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development

Development Antibody Immune Response Production

AbbVie announces acquisition of DJS Antibodies for $255m

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody

Antibody Protein Licensing Licensing

US FDA approves Eisai-Biogen’s antibody for Alzheimer’s

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval

FDA Approval Antibody Clinical Trials Clinical Trials

Salipro partners with Icosagen to develop monoclonal antibody therapies

Pharmaceutical Technology

OCTOBER 10, 2023

The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.

Antibody

Antibody Development Protein

AbCellera and Incyte partner for development of cancer antibodies

Pharmaceutical Technology

SEPTEMBER 14, 2023

AbCellera and Incyte have entered a partnership for the discovery and development of therapeutic antibodies in oncology.

Antibody

Antibody Development

Hospital Universitario and Josep Carreras develop cell therapy for leukaemia

Pharmaceutical Technology

JANUARY 17, 2023

Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia. The Spanish Association Against Cancer (AECC) provided funding for the new STAb therapy development.

Development

Development Gene Therapy Antibody Gene

Almirall and EpimAb partner to develop bispecific antibody therapies

Pharmaceutical Technology

OCTOBER 12, 2023

Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.

Antibody

Antibody Development Licensing Licensing

Diagonal starts up with $128M to make better ‘activator’ antibody drugs

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody

Antibody Drugs Development

TORL BioTherapeutics raises funds to develop new oncology therapies

Pharmaceutical Technology

APRIL 14, 2023

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients.

Development

Development Clinical Trials Clinical Trials Life Science

Leading innovators in anti-influenza antibody compositions for the pharmaceutical industry

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody

Antibody Vaccine Vaccination Dermatology

Basilea wins CARB-X grant for new antibody development

Pharmaceutical Technology

APRIL 9, 2024

The grant will support the preclinical development of the antibody acquired by Basilea from Spexis in January.

Antibody

Antibody Development

Eisai signs agreement with Bliss Biopharmaceutical to develop BB-1701

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. The collaboration will help in further development of BB-1701 across the world and advance the ADC towards late stage of development.

Development

Development Antibody Clinical Trials Clinical Trials

Zenas, with new funding, aims dual-targeting antibody at lupus and MS

Bio Pharma Dive

MAY 7, 2024

The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.

Antibody

Antibody Development

Umoja and IASO partner to develop therapies for haematological malignancies

Pharmaceutical Technology

NOVEMBER 22, 2022

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. The post Umoja and IASO partner to develop therapies for haematological malignancies appeared first on Pharmaceutical Technology.

Development

Development In-Vivo Engineer Clinical Trials

IPA and Ribopro form mRNA antibody discovery collaboration

Pharmaceutical Technology

FEBRUARY 27, 2025

IPA has entered a strategic partnership with Ribopro aiming to transform therapeutic antibody discovery and development.

Antibody

Antibody Development

Uppsala and KTH Royal develop antibody for potential cancer treatment

Pharmaceutical Technology

NOVEMBER 12, 2024

A team of researchers from Uppsala University and KTH Royal Institute of Technology in Sweden has developed a new antibody, which could potentially treat various types of cancer.

Antibody

Antibody Development Research

Astellas to support development of Taysha’s gene therapy programmes

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy

Gene Therapy Gene Development Genetics

Black Diamond spins out new biotech to develop cancer drugs

Bio Pharma Dive

DECEMBER 13, 2022

Months after restructuring and trimming its workforce, the company has teamed up with its original investors to form an antibody drug developer called Launchpad Therapeutics.

Development

Development Drugs Antibody

Ono and EVQLV partner to develop new antibody drugs

Pharmaceutical Technology

DECEMBER 22, 2023

Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.

Antibody

Antibody Development Engineer Drugs

US launches $5bn effort for new Covid-19 vaccines development

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. The programme is expected to develop long-lasting monoclonal antibodies and expedite the development of vaccines that produce mucosal immunity to reduce transmission and infection risks.

Vaccine

Vaccine Vaccination Development Antibody

Novartis, Molecular Partners partner to develop a scalable COVID-19 drug

Bio Pharma Dive

OCTOBER 28, 2020

The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce.

Development

Development Drugs Protein Antibody

Acepodia collaborates with Pfizer to advance antibody-cell conjugation therapies

Pharmaceutical Technology

SEPTEMBER 4, 2024

Pfizer Ignite will support Acepodia in developing its pipeline cancer therapeutic candidates.

Antibody

Antibody Development

German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing

Bio Pharma Dive

MARCH 14, 2024

The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.

Antibody

Antibody Development Drugs

Tourmaline shifts focus to developing anti-IL6 antibody following merger

Pharmaceutical Technology

OCTOBER 20, 2023

The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.

Antibody

Antibody Development Trials

AbbVie and Simcere Zaiming link to develop trispecific antibody

Pharmaceutical Technology

JANUARY 15, 2025

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

Development

Development Antibody Licensing Licensing

BioNTech and DualityBio team up to develop ADC therapeutics for cancer

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. Once developed, the ADCs will join BioNTech’s existing portfolio of oncology products.

Development

Development Sales Antibody Manufacturing

5 FDA approval decisions to watch in the 4th quarter

Bio Pharma Dive

SEPTEMBER 29, 2020

The world's attention will be on the FDA as it considers initial data from coronavirus vaccine developers. But several other important drugs, including a CAR-T therapy and an Ebola antibody, will also be on the agency's agenda.

FDA Approval

FDA Approval Antibody Vaccine Vaccination

Twist rolls out TCR and CAR libraries for cell therapies development

Pharmaceutical Technology

APRIL 14, 2023

Twist Bioscience has introduced Twist T-cell receptor (TCR) and Twist chimeric antigen receptor (CAR) libraries to facilitate the development of cell therapies. Researchers will now be able to speed up the creation of tailor-made libraries that can help in identifying and developing new cell therapies.

Development

Development Gene Therapy Gene Antibody

Regeneron, UPenn to use gene therapy tools to deliver a COVID-19 antibody drug

Bio Pharma Dive

DECEMBER 1, 2020

Working with University of Pennsylvania researcher Jim Wilson, Regeneron aims to develop a nasal spray version of the coronavirus treatment recently cleared by the Food and Drug Administration.

Gene Therapy

Gene Therapy Antibody Gene Drugs

Dantari emerges with a new way to make cancer drug conjugates

Bio Pharma Dive

DECEMBER 8, 2022

As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.

Drugs

Drugs Antibody Medicine Development

FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

Bio Pharma Dive

MARCH 25, 2024

The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.

Antibody

Antibody Drugs Trials Development

Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

Bio Pharma Dive

MARCH 3, 2025

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Licensing

Licensing Licensing Antibody Development

Adagio, after bold promises, says antibody drug won't work well against omicron

Bio Pharma Dive

DECEMBER 15, 2021

Shares in the biotech, which raised nearly $500 million to develop a treatment able to neutralize a wide range of coronavirus variants, plummeted on news of the disappointing laboratory test results.

Antibody

Antibody Drugs Development

Lilly to acquire cancer antibody drug startup Emergence

Bio Pharma Dive

JUNE 29, 2023

The yet-to-be-announced deal for the German biotech is the latest move by Lilly to bulk up its oncology business, adding a drug in early development for solid tumors.

Antibody

Antibody Drugs Development

A startup raises $336M to make a better antibody drug for COVID-19

Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback

Trending Sources

Citryll gains Series B funds to develop NET-targeting antibody

Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

Twist Bioscience and Astellas team up for antibody discovery

Talem and Libera Bio partner for discovery of AI-driven antibodies

FDA approves Regeneron antibody drug as first Ebola virus treatment

Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy

Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China

AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland

Astellas and Sutro partner to develop immunostimulatory ADCs

AbbVie announces acquisition of DJS Antibodies for $255m

US FDA approves Eisai-Biogen’s antibody for Alzheimer’s

Salipro partners with Icosagen to develop monoclonal antibody therapies

AbCellera and Incyte partner for development of cancer antibodies

Hospital Universitario and Josep Carreras develop cell therapy for leukaemia

Almirall and EpimAb partner to develop bispecific antibody therapies

Diagonal starts up with $128M to make better ‘activator’ antibody drugs

TORL BioTherapeutics raises funds to develop new oncology therapies

Leading innovators in anti-influenza antibody compositions for the pharmaceutical industry

Basilea wins CARB-X grant for new antibody development

Eisai signs agreement with Bliss Biopharmaceutical to develop BB-1701

Zenas, with new funding, aims dual-targeting antibody at lupus and MS

Umoja and IASO partner to develop therapies for haematological malignancies

IPA and Ribopro form mRNA antibody discovery collaboration

Uppsala and KTH Royal develop antibody for potential cancer treatment

Astellas to support development of Taysha’s gene therapy programmes

Black Diamond spins out new biotech to develop cancer drugs

Ono and EVQLV partner to develop new antibody drugs

US launches $5bn effort for new Covid-19 vaccines development

Novartis, Molecular Partners partner to develop a scalable COVID-19 drug

Acepodia collaborates with Pfizer to advance antibody-cell conjugation therapies

German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing

Tourmaline shifts focus to developing anti-IL6 antibody following merger

AbbVie and Simcere Zaiming link to develop trispecific antibody

BioNTech and DualityBio team up to develop ADC therapeutics for cancer

5 FDA approval decisions to watch in the 4th quarter

Twist rolls out TCR and CAR libraries for cell therapies development

Regeneron, UPenn to use gene therapy tools to deliver a COVID-19 antibody drug

Dantari emerges with a new way to make cancer drug conjugates

FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

Adagio, after bold promises, says antibody drug won't work well against omicron

Lilly to acquire cancer antibody drug startup Emergence

Stay Connected